Another clinical trial attempting to target both PD1 and CTLA-4 with the different mAbs durvalumab (a PD1 inhibitor) and tremelimumab (a CTLA-4 inhibitor) in unresectable HCC also showed promising results; the combination regimen (tremelimumab 300 mg plus durvalumab 1,500 mg followed by durvalumab 1500 mg once every four weeks) had the best benefit-to-risk profile, with one patient having a complete response (1.3%, 1/75 patients), 17 patients a partial response (22.7%, 17/75 patients), and 16 patients stable (21.3%, 16/75 patients) [56]. Here, CTLA4 is linked to hepatocellular carcinoma.